

BioSyent Inc.

Management's Discussion and Analysis

**For the three and six months ended June 30, 2024
and 2023**

August 26, 2024

Corporate Office
Suite 402
2476 Argentia Road
Mississauga, Ontario, L5N 6M1
Canada
Telephone 905.206.0013
Facsimile 905.206.1413
Email: info@biosyent.com
Web: www.biosyent.com



Table of Contents

1	Introduction
---	---------------------

1	Forward-Looking Statements
1	Accounting Estimates and Accounting Policies

2	Overview, Vision, Strategy, and Products
2	Overview
2	BioSyent's Vision
2	BioSyent's Strategy
4	Pharmaceutical Business
6	Pharmaceutical Product Cycle
6	Pharmaceutical Product Pipeline
6	Pharmaceutical Business Structure
7	Legacy Business
8	New Capabilities and Awards

9	Key Performance Measures
---	---------------------------------

10	Results of Operations for the three and six months ended June 30, 2024 and 2023
11	Expenses
13	Net Income After Taxes (NIAT)
15	Earnings Before Interest, Taxes, Depreciation and Amortization (EBITDA)

16	Earnings per Share (EPS)
----	---------------------------------

17	Financial Resources and Liquidity
----	--

19	Risk Management
----	------------------------

24	Disclosure of Outstanding Share Data
----	---

24	Commitments
24	Office Leases
24	Purchase Commitments

25	Disclosure Controls
----	----------------------------

25	Investor Relations Activities
----	--------------------------------------

25	Related Party Transactions
25	Key Management Personnel Compensation
25	Transactions with Directors

25	Legal Proceedings
----	--------------------------

Introduction

The following discussion of BioSyent Inc.'s ("**BioSyent**" or the "**Company**") operations, performance and financial condition is based on the Company's interim unaudited condensed consolidated financial statements for the three and six months ended June 30, 2024 and June 30, 2023 ("**Consolidated Financial Statements**"), which were prepared in accordance with International Accounting

Standard 34, Interim Financial Reporting ("**IAS 34**"). The discussion of financial condition and results of operations should be read in conjunction with the Consolidated Financial Statements, including the notes thereto. Additional information relating to the Company, including the Consolidated Financial Statements and the accompanying notes can be found at www.sedarplus.ca.

Forward-Looking Statements

This management's discussion and analysis ("**MD&A**") contains or incorporates forward-looking statements within the meaning of Canadian securities legislation (collectively, "forward-looking statements"). These forward-looking statements relate to, among other things, revenue, earnings, changes in costs and expenses, capital expenditures as well as changes in other objectives, strategic plans and business development goals, and may also include other statements that are predictive in nature or depend upon or refer to future events or conditions, and can generally be identified by words such as "may", "will", "expects", "anticipates", "intends", "plans", "believes", "estimates" or similar expressions. In addition, any statements that refer to expectations, projections or other characterizations of future events or circumstances are forward-looking statements. These statements are not historical facts, but instead represent only BioSyent's expectations, estimates, and projections regarding future events.

Although the Company believes the expectations reflected in such forward-looking statements are reasonable, such statements are not guarantees of future performance and involve certain risks and

uncertainties that are difficult to predict. Undue reliance should not be placed on such statements. Certain material assumptions are applied in making forward-looking statements and actual results may differ materially from those expressed or implied in such statements. Known and unknown factors could cause actual results to differ materially from those expressed or implied in the forward-looking statements. Important assumptions, influencing factors, risks, and uncertainties are referred to in the body of this MD&A, in the press release announcing the Company's financial results for the three and six months ended June 30, 2024 and June 30, 2023 and in BioSyent's annual and interim financial statements and the notes thereto. These documents are available at www.sedarplus.ca.

The forward-looking statements contained in this MD&A are made as at the date of this MD&A and, accordingly, are subject to change after such date. Except as required by law, BioSyent does not undertake any obligation to update or revise any forward-looking statements made or incorporated in this MD&A, whether as a result of new information, future events or otherwise.

Accounting Estimates and Accounting Policies

The Company has not early adopted any standards, interpretations or amendments that have been issued but are not yet effective.

The preparation of the Company's Consolidated Financial Statements requires management to make critical judgments, estimates, and assumptions that affect the reported amounts of revenues, expenses, assets and liabilities, and the disclosure of contingent liabilities, at the reporting date. On an ongoing basis, management evaluates its judgments, estimates, and assumptions using historical experience and various other factors it believes to be reasonable under the given circumstances. In the future, actual experience may differ from these estimates and assumptions.

BioSyent's significant accounting judgments and estimates include recoverability of asset carrying values, impairment of trade and other receivables, income taxes, the future useful lives and residual values of equipment, the useful lives of intangible assets, the fair value of share-based payments, the value of inventory, determination of the transaction price in revenue recognition, and determination of the incremental borrowing rate and lease term in leases. For a more detailed discussion of changes to the Company's critical accounting estimates, please refer to Note 4 of the Consolidated Financial Statements for the year ended December 31, 2023.

Non-IFRS Financial Measures

This MD&A makes reference to certain non-IFRS measures. These non-IFRS measures are not recognized measures under IFRS and do not have a standardized meaning prescribed by IFRS and are unlikely to be comparable to similar measures presented by other companies. When used, these measures are defined in such terms as to allow the reconciliation to the closest IFRS measure. These measures are provided as additional information to complement those IFRS measures by providing a further understanding of the Company's results of operations from management's perspective.

Accordingly, these measures should not be considered in isolation nor as a substitute for analyses of the Company's financial information reported under IFRS. Management uses non-IFRS measures such as Earnings Before Interest, Taxes, Depreciation and Amortization ("**EBITDA**") an Trailing Twelve Months Earnings Per Share ("**TTM EPS**") to provide investors with supplemental measures of the Company's operating performance and thus highlight trends in the Company's core business that may not otherwise be apparent when relying solely on IFRS financial measures. Management also believes that securities analysts, investors, and other interested parties frequently use non-IFRS measures in the evaluation of issuers. Management also uses non-IFRS measures in order to facilitate operating performance comparisons from period to period, prepare annual operating budgets, and to

assess the Company's ability to meet future debt service, capital expenditure, and working capital requirements. The definition and a reconciliation of EBITDA, as used and presented by the Company, to the most directly comparable IFRS measures follows later in this MD&A.

Overview, Vision, Strategy, and Products

Overview

BioSyent is a publicly traded specialty pharmaceutical company which, through its wholly owned subsidiaries, BioSyent Pharma Inc. (“**BioSyent Pharma**”) and BioSyent Pharma International Inc., sources, acquires or in-licences and further develops pharmaceutical and other healthcare products for sale in Canada and certain international markets. Hedley Technologies Ltd. and Hedley Technologies (USA) Inc., also wholly owned subsidiaries of BioSyent, operate the Company's legacy business, marketing biologically and health friendly non-chemical insecticides (the “**Legacy Business**”). BioSyent's issued and outstanding common shares (the “**Common Shares**”) are listed for trading on the TSX Venture Exchange under the symbol “RX”.

BioSyent's Vision

BioSyent's vision is to be the leading independent Canadian provider of innovative healthcare products.


BioSyent's Strategy

BioSyent's strategic focus is on commercializing innovative products with recognizable brand equity sourced through international partnerships. These products are unique due to manufacturing complexities, novel technologies, therapeutic advantages and strong, defensible intellectual property rights. The Company works with and supports healthcare practitioners in improving patient lives.

The Company reviews its strategy and performance against its strategic objectives on an ongoing basis.

BioSyent's strategy has three components:

1. Growth (Revenue and Profit);
2. Diversification; and
3. Corporate Longevity.



These three strategic components are prioritized in any investment and capital allocation decision made by the Company, including any decision to return capital to shareholders through the payment of dividends or through share buybacks.

Growth:

The Company uses various means of achieving its revenue growth objectives while reducing risk in the marketplace. The Company adopts an accelerating investment approach in promoting its products in the marketplace by balancing its investment behind brands with revenue and growth and by segmenting the market into immediate and long-term growth opportunities. It pursues possible reimbursement avenues for its products in both the private and public sectors. The Company employs a salesforce of qualified sales professionals across Canada with experience in pharmaceutical detailing to healthcare practitioners and hospitals. The Company supports its salesforce by using various marketing techniques throughout the product life cycle, as it deems appropriate, including healthcare practitioner detailing, direct to patient information through various media, product differentiation materials, and expansion of patient and healthcare practitioner support services to increase awareness of product efficacy and safety.

In addition to organic growth from its existing product portfolio, incremental growth from adding new products to its portfolio is essential to the Company's growth strategy, both in the near-term and long-term.

Diversification:

BioSyent has developed sourcing arrangements with partners from around the world. The Company's flexible format does not limit the scope of diversification opportunities it considers for both new and existing products or sales channels. In building its product portfolio, the Company considers accretive asset and business acquisition opportunities and in-licensing opportunities for products which can drive profitable growth in the near-term and long-term.

The Company exercises diligence when sourcing new products. Some of the steps in this process involve financial modeling, comparison against investment criteria benchmarks and financial metrics, reviewing market data and market trends, interviewing key healthcare practitioners or medical advisory boards and obtaining opinions on reimbursement possibilities with payers. BioSyent evaluates all new product opportunities against specific financial benchmarks with the objective of acquiring or in-licensing quality assets which will provide a long-term return that is consistent with or supportive of the Company's existing product portfolio.

Once the Company has decided to proceed with a new product opportunity, it acquires or licenses exclusive Canadian and/or international market rights to that product. After the acquisition or in-licensing of the product, the Company manages the product through the regulatory and product registration process and, once approved, commercializes the product in Canada and/or international markets.

Corporate Longevity:

On an aggregate basis, the Company manages its product portfolio to maintain specific annual and long-term financial ratios, including revenue and profit CAGR and Return on Equity, in order to achieve its strategic objectives. The Company maintains a discipline in acquiring or in-licensing new products which are accretive in terms of both sales and profitability over the long-term. The level of ultimate commercial success of a new product in the market is not known at the time it is in-licensed or acquired by the Company. The Company evaluates the commercial performance of each of its products on an ongoing basis and manages the level of its investments in marketing and promotional activities with an objective of maximizing long-term sales growth and profitability overall.

This strategy allows the Company to market these products as brands it owns or licenses. By virtue of its strong growth record, the Company is able to attract partners for new products that have niche positioning.

Evolution of Strategy

BioSyent considers opportunities based on its strategic objectives. From time to time, the Company may acquire or in-license opportunities in late-stage development with which it, or its partners, have significant prior experience. Such experience and competency of the Company and its partners give the Company the ability to gauge risk in some depth. The Company may also seek in-licensing opportunities for new products launched in countries outside of Canada that require additional research and development work before being launched in the Canadian market. The Company considers opportunities where there is a high probability that additional research and development work is likely to extend the lifecycle of portfolio products. Such studies might include in vitro or in vivo studies (including bio-equivalency studies, efficacy studies, or safety studies).

Ultimately, BioSyent is focused on products which can deliver superior growth and return on investment. As well as acquiring or in-licensing such products, as part of BioSyent's ongoing evaluation of its product portfolio, BioSyent may de-emphasize or even discontinue the sale of certain products in order to maintain its strategic focus and resource allocation on the best opportunities in terms of growth and profitability.

Pharmaceutical Business

FeraMAX[®] Pd Therapeutic 150



In 2007, BioSyent Pharma launched FeraMAX[®] 150, an oral iron supplement, in Canada. In 2016, the Company developed a 100 mg formulation of FeraMAX[®] capsules (“FeraMAX[®] 100”) for distribution in certain markets outside of Canada.

In 2020, BioSyent Pharma launched FeraMAX[®] Pd Therapeutic 150 in Canada, replacing FeraMAX[®] 150 at Canadian pharmacies. FeraMAX[®] Pd Therapeutic 150 is the first product launched under the trusted FeraMAX[®] brand using a new patented delivery system for the treatment of iron deficiency anemia based on a Polydextrose Iron Complex (“PDIC”) formulation. FeraMAX[®] Pd Therapeutic 150 is Vegan Certified and is also recognized by the Society of Obstetricians and Gynaecologists of Canada.

FeraMAX[®] Pd Powder 15



In 2013, BioSyent Pharma launched FeraMAX[®] Powder, an oral iron product in a dissolvable, pleasant-tasting powder, in Canada. The Company has also launched the product in several international

markets through distribution agreements.

In 2021, BioSyent Pharma launched FeraMAX[®] Pd Powder 15 in Canada, replacing FeraMAX[®] Powder at Canadian pharmacies. FeraMAX[®] Pd Powder 15 is the second product launched using the patented PDIC formulation and makes iron therapy convenient for children.

FeraMAX[®] Pd Maintenance 45



In 2023, BioSyent Pharma launched FeraMAX[®] Pd Maintenance 45 in Canada. This is the third and newest FeraMAX[®] Pd product developed by the Company based on the patented PDIC platform. FeraMAX[®] Pd

Maintenance 45 is a chewable, orange-flavoured iron supplement containing 45 mg of elemental iron as well as 75 mg of vitamin C and 1,000 mcg of vitamin B12. FeraMAX[®] Pd Maintenance 45 enhances the Company’s line of FeraMAX[®] Pd products for the management of iron health, offering patients an innovative solution to maintaining healthy iron levels.

Cathejell[®]

Cathejell[®]

2% lidocaine hydrochloride jelly, USP

Cathejell[®] was in-licensed by BioSyent Pharma from a European partner in

2009. In 2012, BioSyent Pharma launched Cathejell[®] in Canada. Cathejell[®] combines a sterile gel with lidocaine in a unique collapsible applicator syringe to ease patient discomfort for a range of medical procedures. Cathejell[®] is indicated for surface anesthesia and lubrication for various procedures including male and female cystoscopies, catheterizations and other endourethral operations, endoscopies, proctoscopies, rectoscopies and tracheal intubations. Cathejell[®] can also be used for the symptomatic treatment of pain in connection with cystitis and urethritis.

RepaGyn[®]

RepaGyn[®]

RepaGyn[®] was in-licensed by BioSyent Pharma from a European partner in 2013. In 2014, BioSyent

Pharma launched RepaGyn[®] in Canada. RepaGyn[®] is an innovative vaginal suppository recommended for relieving vaginal dryness and healing of the vaginal mucosa. RepaGyn[®], a natural health product, is formulated with sodium hyaluronate and provides a hormone-free treatment proven to deliver symptom relief, and tissue repair.

Proktis-M[®]

Proktis-M[®]

Rectal Suppositories • Sodium Hyaluronate

Proktis-M[®] was in-licensed by BioSyent Pharma from a European partner in 2014. In 2014, BioSyent

Pharma launched Proktis-M[®] in Canada. Proktis-M[®] rectal suppositories are designed to help the healing of the anus and rectum. Proktis-M[®] rectal suppositories have been studied and tested in conditions such as operated severe internal hemorrhoids, anal fissures, and prevention of radiation-induced proctitis. Proktis-M[®] rectal suppositories are formulated with sodium hyaluronate, a naturally occurring compound, and offer a temporary matrix to facilitate cell proliferation which enhances wound healing.

Tibella[®]



Tibella[®] was in-licensed from a European partner in 2016. In 2020, BioSyent Pharma launched Tibella[®] in Canada. Tibella[®], a prescription

product, is a hormone replacement therapy (“HRT”) consisting of tibolone. Tibella[®] is indicated for the short-term treatment of vasomotor symptoms due to estrogen deficiency in postmenopausal women, more than one year after menopause.

Combogesic®

Combogesic® was in-licensed from a partner in 2019. In 2020, BioSyent Pharma launched Combogesic® in Canada. Combogesic® combines two well-known and effective medicines, acetaminophen and ibuprofen, in a single form that has been demonstrated to synergistically provide pain relief.

Inofolic®

inofolic® In 2020, BioSyent Pharma signed an exclusive License and Supply Agreement with a European partner for a new women's health product, Inofolic®, for the Canadian market. Inofolic® is a natural health product, combining myo-inositol and folic acid in a soft-gel capsule for the management of the symptoms of Polycystic Ovary Syndrome (PCOS), an endocrine disorder affecting many aspects of a woman's health, including insulin resistance, infertility, menstrual dysfunction and skin manifestations such as acne, hirsutism (excess hair growth) and alopecia (hair loss). Inofolic® has been approved for sale in Canada, the U.S.A., Europe and in several other markets around the world. BioSyent Pharma Inc. launched Inofolic® in Canada in August 2023.

Gelclair®


gelclair® In 2022, BioSyent Pharma signed a Distribution Agreement with a European partner to acquire an exclusive license to use certain trademarks and to distribute an oncology supportive care product, Gelclair®, in Canada. Gelclair® is a viscous gel specially formulated to aid in soothing the pain of oral mucositis by forming a protective film barrier that adheres to the mucosa of the mouth to protect the nerve endings that cause pain from further irritation and to hydrate and coat damaged tissue. Oral mucositis is a painful inflammation and ulceration of the mucous membranes in the mouth and throat often experienced by patients undergoing radiation or chemotherapy for cancer or bone marrow transplant. Having obtained the necessary regulatory approvals from Health Canada, BioSyent Pharma Inc. commenced promoting Gelclair® in Canada through its Specialty Business Unit in July 2023. BioSyent Pharma Inc. commenced distribution of Gelclair® in Canada in November 2023.

New Endocrinology Product

In 2024, BioSyent Pharma signed a License and Supply Agreement with a European partner to acquire an exclusive license to register, market, sell and distribute a new endocrinology product for Canada. BioSyent Pharma and its European partner have agreed to seek Health Canada approval of the product by the end of 2024.

Pharmaceutical Product Cycle

The Company organizes its product lifecycle into six stages: (i) in-license stage, (ii) regulatory stage, (iii) pre-launch stage, (iv) launch stage, (v) growth stage, and (vi) maturity stage.



The Company currently has three products in the maturity stage (Cathejell[®], RepaGyn[®] and Proktis-M[®]), four products in the growth stage (Feramax[®] Pd Therapeutic 150, Feramax[®] Pd Powder 15, Tibella[®], and Combogesic[®]), three products in the launch stage (Feramax[®] Pd Maintenance 45, Inofolic[®] and Gelclair[®]), and two


products in the regulatory stage (a new endocrinology product and a new Feramax[®] Pd product in development). New product acquisition opportunities can occur throughout the product lifecycle stages illustrated above.

Pharmaceutical Product Pipeline

The Company is committed to expanding its product portfolio and accelerating its product pipeline with a focus on innovative products that are unique. Although launched in markets outside of Canada, some of these products may require additional investment before the Company seeks approval from Health Canada for the Canadian market.

Pharmaceutical Business Structure

The Company has three pharmaceutical business units: (i) the Community and Women's Health Business Unit which commercializes pharmaceutical products focused on improving family and women's health in Canada (the "**Community Business**"); (ii) the Specialty Business Unit which sells pharmaceutical and healthcare products to Canadian hospitals and specialists (the "**Specialty Business**"); and (iii) the International Pharmaceutical Business Unit which sells Feramax[®] to markets outside of Canada (the "**International Business**").



These three business units, collectively, the “**Pharmaceutical Business**”, as well as the Legacy Business, are supported by the Company’s Corporate Operations, including the finance, supply chain and logistics, medical and regulatory affairs, information technology, business development, market access, human resources, business intelligence, and legal functions. As the Company expands its product portfolio into new therapeutic areas, new business units may be established as part of the pharmaceutical business structure as and when considered appropriate.

Legacy Business

Protect-It®

The Company continues to manufacture and market Protect-It®, a bio-friendly, non-chemical, food-safe grain insecticide. Protect-It® was developed through collaborative research between the Cereal Research Centre of Agriculture and Agri-Food Canada. Protect-It® is used as a preventative treatment against insect infestations in stored grains. The Legacy Business provides an additional source of cash flows for the Company allowing it to focus on its strategic areas of growth in the Pharmaceutical Business.

New Capabilities and Awards

TSX Venture 50



On February 21, 2024, BioSyent Inc. was named to the 2024 TSX Venture 50 list in the Clean Technology and Life Sciences category as one of the top performers on the TSX Venture Exchange. The TSX Venture 50 recognizes the top 10 companies from each of five sectors: Clean Technology and Life Sciences, Diversified Industries, Energy, Mining, and Technology. The companies are ranked based on three equally-weighted criteria: share price appreciation, market capitalization growth, and trading value.

FeraMAX® #1 for Ninth Consecutive Year



On April 3, 2024, the Company's FeraMAX® brand was named the #1 Pharmacist and Physician recommended over-the-counter oral iron supplement brand in Canada for the ninth consecutive year (*EnsembleIQ Research and Innovation: Pharmacy Practice + Business, The Medical Post, Profession Santé,*

CanadianHealthcareNetwork.ca, and ProfessionSanté.ca 2024 Survey on OTC Counselling and Recommendations).

New Endocrinology Product

On June 12, 2024, the Company announced that BioSyent Pharma had signed a License and Supply Agreement with a European partner to acquire an exclusive license to register, market, sell and distribute a new endocrinology product for Canada which management believes has significant revenue growth potential. BioSyent Pharma and its European partner have agreed to seek Health Canada approval of the product by the end of 2024.

Key Performance Measures

A summary of key performance measures for the second quarter (“Q2”) and first half (“H1”) ended June 30, 2024 and June 30, 2023 are presented in the following tables along with the preceding three quarters, with commentary on the Company’s overall financial performance below.

Key Performance Measure	H1 2024	% Change vs. H1 2023	% to Total Company Sales	Q2 2024	% Change vs. Q2 2023	% to Total Company Sales	Q1 2024	Q4 2023	Q3 2023
Canadian Pharma Sales	16,081,624	14%	96%	8,535,480	11%	95%	7,546,144	7,989,098	7,432,361
International Pharma Sales	157,217	n/a	1%	157,217	n/a	2%	-	54,750	992,997
Legacy Business Sales	439,361	41%	3%	251,869	4%	3%	187,492	229,838	445,764
Total Company Sales	16,678,202	15%	100%	8,944,566	12%	100%	7,733,636	8,273,686	8,871,122
Gross Profit	13,214,709	12%	79%	7,070,835	9%	79%	6,143,874	6,704,505	7,062,098
EBITDA	4,252,264	26%	25%	2,048,071	10%	23%	2,204,193	1,650,301	2,899,612
NIAT	3,349,016	26%	20%	1,580,289	7%	18%	1,768,727	1,450,791	2,350,900
Diluted EPS	0.28	27%		0.13	8%		0.15	0.12	0.20
Net Change in Cash, Short term and Long term Investments	(2,878,796)			(1,986,128)			(892,668)	(602,603)	1,367,061

Key Performance Measure	H1 2023	% Change vs. H1 2022	% to Total Company Sales	Q2 2023	% Change vs. Q2 2022	% to Total Company Sales	Q1 2023	Q4 2022	Q3 2022
Canadian Pharma Sales	14,133,440	12%	98%	7,721,746	23%	97%	6,411,694	7,289,023	6,371,751
International Pharma Sales	-	-100%	0%	-	0%	0%	-	117,791	-
Legacy Business Sales	312,054	-39%	2%	241,054	-34%	3%	71,000	55,116	419,220
Total Company Sales	14,445,494	6%	100%	7,962,800	20%	100%	6,482,694	7,461,930	6,790,971
Gross Profit	11,831,340	7%	82%	6,496,608	19%	82%	5,334,732	6,193,608	5,609,449
EBITDA	3,376,565	-14%	23%	1,859,931	10%	23%	1,516,634	1,568,032	1,949,019
NIAT	2,658,436	-5%	18%	1,483,190	22%	19%	1,175,246	1,199,516	1,453,042
Diluted EPS	0.22	0%		0.12	20%		0.10	0.09	0.12
Net Change in Cash, Short term and Long term Investments	(773,091)			1,673,068			(2,446,159)	910,999	(113,905)

The Company reported its highest ever quarterly sales in Q2 2024 of \$8,944,566, increasing by 12% over the comparative Q2 2023 and by 16% over the prior quarter, Q1 2024. This growth was driven by record Canadian pharmaceutical sales of \$8,535,480. All of the Company’s Canadian pharmaceutical products delivered sales growth during the quarter with Feramax[®] Pd and Tibella[®] being the largest contributors to this growth.

This double-digit sales growth in Q2 2024 follows strong growth in Q1 2024. When combined, total Company sales growth for H1 2024 was 15% over H1 2023, driven by 14% sales growth in the Canadian pharmaceutical business.

While the Company’s Net Income After Tax (NIAT) for Q2 2024 of \$1,580,289 increased by 7% over Q2 2023, its NIAT margin declined to 18% of sales in Q2 2024 from 19% of sales in Q2 2023 as a result of a higher ratio of selling and marketing expenditures to revenues for its launch-stage brands, Feramax[®] Pd Maintenance 45, Inofolic[®] and Gelclair[®], during the quarter.

H1 2024 NIAT of \$3,349,016 increased by 26% over the comparative period with a NIAT margin of 20% improving from a NIAT margin of 18% in H1 2023. Although aggregate gross margins declined from the comparative period, the ratio of the Company’s operating expenses (excluding the cost of goods sold and finance costs/income), declined to 55% of sales in H1 2024 from 60% of sales in H1 2023. This ratio improved in H1 2024 as a result of 15% total Company sales growth compared with a 9% increase in selling and marketing expenses and flat general and administrative expenses.

Results of Operations for the three and six months ended June 30, 2024 and 2023

Total Company Sales:

Q2 2024 vs. Q2 2023

The Company reported its highest ever quarterly sales in Q2 2024 of \$8,944,566, increasing by 12% compared to Q2 2023 sales of \$7,962,800 which increased by 20% compared to Q2 2022. Growth during Q2 2024 was driven by Canadian pharmaceutical sales, as mentioned above, with further growth over the comparative quarter contributed by the international pharmaceutical business and legacy business.

H1 2024 vs. H1 2023

Total Company sales for the first half of 2024 of \$16,678,202 increased by 15% over the comparative period, driven by 14% growth in Canadian pharmaceutical sales, combined with strong growth in international pharmaceutical sales and legacy business sales over the comparative period.

Canadian Pharmaceutical Sales:

Q2 2024 vs. Q2 2023

Canadian pharmaceutical sales for Q2 2024 were a record \$8,535,480, increasing by 11% versus Q2 2023 sales of \$7,721,746 which increased by 23% compared to Q2 2022.

The table below summarizes the Q2 2024 versus Q2 2023 percentage change in sales (dollars) by brand:

Brand	Q2 2024 vs. Q2 2023 Change
Feramax® Pd	+7%
RepaGyn®	+8%
Tibella®	+40%
Combogesic®	+77%
Inofolic®	*
Cathejell®	+5%
Gelclair®	*

*Newly-launched product – \$nil comparative sales for Q2 2023

All of the Company's Canadian pharmaceutical brands contributed to sales growth in Q2 2024 with Feramax® Pd and Tibella® being the largest contributors to this growth in dollars.

The Company's launch brands, Feramax® Pd Maintenance 45, Inofolic®, and Gelclair® all contributed incremental sales growth during the quarter, though their proportional contribution was modest.

H1 2024 vs. H1 2023

With double-digit sales growth in both Q1 and Q2 2024, Canadian pharmaceutical sales for H1 2024 were \$16,081,624, increasing by 14% versus H1 2023 sales of \$14,133,440 which increased by 12% compared to H1 2022.

The table below summarizes the H1 2024 versus H1 2023 percentage change in sales (dollars) by brand:

Brand	H1 2024 vs. H1 2023 Change
Feramax® Pd	+11%
RepaGyn®	+16%
Tibella®	+36%
Combogesic®	+100%
Inofolic®	*
Cathejell®	+3%
Gelclair®	*

*Newly-launched product – \$nil comparative sales for H1 2023

All of the Company's Canadian pharmaceutical brands contributed to sales growth in H1 2024, with double-digit percentage growth for the Feramax® Pd product suite, RepaGyn® and Tibella® over the comparative period with continued demand growth for these products from patients. Combogesic® sales doubled in H1 2024 over the comparative period (during which sales declined by 18% versus H1 2022).

The Company's launch brands, Feramax® Pd Maintenance 45, Inofolic®, and Gelclair®, all contributed incremental sales growth during the period.

International Pharmaceutical Sales:

Q2 2024 vs. Q2 2023

International FeraMAX® sales were \$157,217 in Q2 2024 as compared to \$nil in Q2 2023 as a result of a single, large shipment to an international market during the quarter.

H1 2024 vs. H1 2023

With one shipment in Q2 2024, international FeraMAX® sales were \$157,217 in H1 2024 as compared to \$nil in H1 2023.

The Company continues to experience unevenness in the timing of international FeraMAX® sales to its export markets from period to period as the Company's distribution partners navigate the regulatory, geopolitical, logistical and trade challenges of the business environment in certain of these markets. Though the Company is planning for the delivery of further international FeraMAX® orders in the second half of 2024, there is some level of uncertainty due to continued political instability and conflict in the destination markets.

Legacy Business Sales:

Q2 2024 vs. Q2 2023

Protect-It[®] sales for Q2 2024 were \$251,869, increasing by 4% from Q2 2023 sales of \$241,054 which decreased by 34% as compared to Q2 2022.

H1 2024 vs. H1 2023

Protect-It[®] sales for H1 2024 were \$439,361, increasing by 41% from H1 2023 sales of \$312,054 which decreased by 39% as compared to H1 2022. Timing of demand for grain insecticides influenced by several factors, including weather conditions, prices of agricultural inputs, the quality and quantity of the food grain harvest, and the level of infestation of stored grain.

Expenses

Q2 2024 vs. Q2 2023

	Q2 2024	% Change vs. Q2 2023	% to Total Company Sales	Q2 2023	% Change vs. Q2 2022	% to Total Company Sales
Cost of goods sold	\$1,873,731	28%	21%	\$1,466,192	25%	18%
Selling and marketing	\$3,543,767	18%	40%	\$3,009,742	25%	38%
General and administration	\$1,555,225	-9%	17%	\$1,701,188	17%	21%
New business development costs	\$45,569	22%	1%	\$37,377	206%	0%
Finance costs	\$15,009	-13%	0%	\$17,343	-11%	0%
Subtotal	\$7,033,301	13%	79%	\$6,231,842	23%	78%
Finance income	\$ (238,789)	-17%	3%	\$ (286,988)	267%	4%

Total expenses for Q2 2024 (including the cost of goods sold) were \$7,033,301, increasing by 13% overall versus Q2 2023 expenses of \$6,231,842 which increased by 23% versus Q2 2022. The ratio of total expenses to sales in Q2 2024 was 79%, increasing from a ratio of 78% in Q2 2023.

The cost of goods sold increased to 21% of sales in Q2 2024 as compared to 18% in Q2 2023 with continued input cost pressures on certain products, foreign exchange impacts, and changes in sales mix impacting the overall gross margin.

Total selling and marketing expenses for Q2 2024 were \$3,543,767, increasing by 18% as compared to Q2 2023 selling and marketing expenses of \$3,009,742, which increased by 25% compared to Q2 2022. During Q2 2024, the Company redeployed certain employee costs and continued to support the launch of Inofolic[®] (launched in August 2023) and Gelclair[®] (launched in November 2023) through selling and marketing investment, as well as continued marketing support of the Feramax[®] Pd Maintenance 45 product which was launched in March 2023. While these launch brands generated incremental revenue during the quarter, such revenue growth was outpaced by planned selling and marketing investments as these launch brands gain traction in the market. As a result of this continued investment in the promotion of launch brands, the overall ratio of selling and marketing expenses increased to 40% of sales overall in Q2 2024 as compared to 38% in Q2 2023 even as total Company sales grew by 12% in Q2 2024 versus Q2 2023.

General and administration expenses for Q2 2024 were \$1,555,225, decreasing by 9% as compared to Q2 2023 general and administration expenses of \$1,701,188. This decrease was a result of non-recurring credit losses on accounts receivable incurred in the comparative quarter as well as an internal redeployment of certain employee costs. With 12% overall sales growth, the ratio of general and administration expenses to total Company sales was 17% for Q2 2024, decreasing from a ratio of 21% in Q2 2023.

Finance income for Q2 2024, consisting of interest earned on short term and long term investments, was \$238,789, decreasing by 17% as compared to Q2 2023 finance income of \$286,988 as a result of an overall decrease in total cash and investments in Q2 2024 as compared to Q2 2023.

H1 2024 vs. H1 2023

	H1 2024	% Change vs. H1 2023	% to Total Company Sales	H1 2023	% Change vs. H1 2022	% to Total Company Sales
Cost of goods sold	\$3,463,493	32%	21%	\$2,614,154	0%	18%
Selling and marketing	\$6,019,173	9%	36%	\$5,545,290	20%	38%
General and administration	\$3,070,378	0%	18%	\$3,078,089	15%	21%
New business development costs	\$109,679	105%	1%	\$53,442	67%	0%
Finance costs	\$30,602	-13%	0%	\$35,052	-11%	0%
Subtotal	\$12,693,325	12%	76%	\$11,326,027	13%	78%
Finance income	\$ (571,608)	15%	3%	\$ (497,453)	312%	3%

Total expenses for H1 2024 (including the cost of goods sold) were \$12,693,325, increasing by 12% overall versus H1 2023 expenses of \$11,326,027 which increased by 13% versus H1 2022. The ratio of total expenses to sales in H1 2024 was 76%, decreasing from a ratio of 78% in H1 2023.

The cost of goods sold increased to 21% of sales in H1 2024 as compared to 18% in H1 2023 with continued input cost pressures on certain products, foreign exchange impacts, and changes in sales mix impacting the overall gross margin.

Total selling and marketing expenses for H1 2024 were \$6,019,173, increasing by 9% as compared to H1 2023 selling and marketing expenses of \$5,545,290, which increased by 20% compared to H1 2022. While the Company continued to invest in the promotion of its three launch brands (Feramax[®] Pd Maintenance 45, Inofolic[®], and Gelclair[®]), which delivered incremental sales growth, its established Canadian pharmaceutical brands delivered double-digit sales growth during the period. As a result, the overall ratio of selling and marketing expenses decreased to 36% of sales overall in H1 2024 as compared to 38% in H1 2023. Management plans to make further selling and marketing investment in its three launch products in 2024 to support their growth trajectory in their respective markets.

General and administration expenses for H1 2024 were \$3,070,378, decreasing marginally as compared to H1 2023 general and administration expenses of \$3,078,089. As a result of 15% overall sales growth, the ratio of general and administration expenses to total Company sales decreased to 18% in H1 2024 from 21% in H1 2023.


Finance income for H1 2024, consisting of interest earned on short term and long term investments, was \$571,608, increasing by 15% as compared to H1 2023 finance income of \$497,453 as a result of higher overall yields on short term investments in the first quarter of 2024 as compared to the first quarter of 2023.

Net Income After Taxes (NIAT)

Q2 2024 vs. Q2 2023

NIAT for Q2 2024 of \$1,580,289 increased by 7% compared to NIAT for Q2 2023 of \$1,483,190 which increased by 22% compared to Q2 2022. The Company's NIAT margin for Q2 2024 was 18% to sales as compared to 19% to sales in Q2 2023 as a result of lower gross margins and an increase in selling and marketing expenditures on launch brands during the quarter while total Company sales grew by 12%.

Sales and Net Income Before & After Tax For the three months (Q2) ended June 30




Including currency translation gains of \$314, total comprehensive income for Q2 2024 was \$1,580,603, increasing by 6% compared to total comprehensive income for Q2 2023 of \$1,497,668, which increased by 20% compared to total comprehensive income for Q2 2022.

H1 2024 vs. H1 2023

NIAT for H1 2024 of \$3,349,016 increased by 26% compared to NIAT for H1 2023 of \$2,658,436 which decreased by 5% compared to H1 2022. The Company's NIAT margin for H1 2024 was 20% to sales as compared to 18% to sales in H1 2023 as a result of 15% total Company sales growth during the period and a decline in the ratio of the Company's operating expenses (excluding the cost of goods sold and finance costs/income) to 55% of sales in H1 2024 from 60% of sales in H1 2023.

**Sales and Net Income Before & After Tax
For the six months (H1) ended June 30**




Including currency translation gains of \$492, total comprehensive income for H1 2024 was \$3,349,508, increasing by 24% compared to total comprehensive income for H1 2023 of \$2,703,124, which decreased by 4% compared to total comprehensive income for H1 2022.

Earnings Before Interest, Taxes, Depreciation and Amortization (EBITDA)

EBITDA is a non-IFRS financial measure. The term EBITDA does not have any standardized meaning under IFRS and therefore may not be comparable to similar measures presented by other companies. The Company defines EBITDA as earnings before

interest income and/or expense, income taxes, depreciation and amortization. A summary of the Company's EBITDA for the three and six months ended June 30, 2024, 2023, and 2022 is provided in the graph below:

EBITDA for the three and six months ended June 30



Q2 2024 vs. Q2 2023

EBITDA for Q2 2024 of \$2,048,071 increased by 10% compared to EBITDA for Q2 2023 of \$1,859,931 which increased by 10% compared to Q2 2022. The Company's EBITDA margin of 23% to sales for Q2 2024 was consistent with such margin for Q2 2023.

A reconciliation of EBITDA to NIAT for the three months ended June 30, 2024, 2023, and 2022 is provided in the table below:

RECONCILIATION OF EBITDA TO NIAT FOR THE THREE MONTHS (Q2) ENDED JUNE 30

	2024	2023	2022
Q2 EBITDA	\$2,048,071	\$1,859,931	\$1,688,583
Add: Interest Income	238,789	286,988	78,273
Less: Depreciation of Property and Equipment	(69,647)	(71,543)	(75,361)
Amortization of Intangible Assets	(52,150)	(40,087)	(22,862)
Interest Expense	(15,009)	(17,343)	(19,502)
Income Tax Expense	(569,765)	(534,756)	(431,248)
Q2 NIAT	\$1,580,289	\$1,483,190	\$1,217,883

H1 2024 vs. H1 2023

EBITDA for H1 2024 of \$4,252,264 increased by 26% compared to EBITDA for H1 2023 of \$3,376,565 which decreased by 14% compared to H1 2022. The Company's EBITDA margin of 25% to sales for H1 2024 improved from an EBITDA margin of 23% to sales for H1 2023 as a result of 15% total Company sales growth

combined with a decline in the overall ratio of operating expenses to sales in H1 2024 versus H1 2023, increasing operating profit overall.

A reconciliation of EBITDA to NIAT for the six months ended June 30, 2024, 2023, and 2022 is provided in the table below:

RECONCILIATION OF EBITDA TO NIAT FOR THE SIX MONTHS (H1) ENDED JUNE 30

	2024	2023	2022
H1 EBITDA	\$4,252,264	\$3,376,565	\$3,915,945
Add: Interest Income	571,608	497,453	120,766
Less: Depreciation of Property and Equipment	(138,809)	(142,798)	(150,722)
Amortization of Intangible Assets	(97,976)	(79,248)	(47,388)
Interest Expense	(30,602)	(35,052)	(39,295)
Income Tax Expense	(1,207,469)	(958,484)	(993,519)
H1 NIAT	\$3,349,016	\$2,658,436	\$2,805,787

Earnings per Share (EPS)

Below is a summary of the Company's quarterly sales, NIAT, and EPS for the eight most recently completed quarters:

	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022	Q2 2022
Total Company Sales (\$)	8,944,566	7,733,636	8,273,686	8,871,122	7,962,800	6,482,694	7,461,930	6,790,971	6,634,875
Net Income After Taxes (\$)	1,580,289	1,768,727	1,450,791	2,350,900	1,483,190	1,175,246	1,199,516	1,453,042	1,217,883
Earnings Per Share – Basic (\$)	0.14	0.15	0.12	0.20	0.12	0.10	0.09	0.12	0.10
Earnings Per Share – Fully Diluted (\$)	0.13	0.15	0.12	0.20	0.12	0.10	0.09	0.12	0.10
TTM EPS – Diluted (\$)	0.60	0.59	0.53	0.50	0.43	0.41	0.44	0.49	0.50

Fully diluted EPS for Q2 2024 was \$0.13, increasing by \$0.01 compared with fully diluted EPS of \$0.12 for Q2 2023 which increased by \$0.02 versus Q2 2022.

Fully diluted EPS for H1 2024 was \$0.28, increasing by \$0.06 compared with fully diluted EPS of \$0.22 for H1 2023 which was consistent with H1 2022.

Fully diluted EPS for the trailing twelve months ("TTM") ended June 30, 2024 was \$0.60, increasing by \$0.17 compared with fully diluted EPS of \$0.43 for the TTM ended June 30, 2023.

Financial Resources and Liquidity

Working capital, defined here as the difference between current assets and current liabilities, decreased to \$25,190,060 as at June 30, 2024 from \$30,337,631 as at December 31, 2023 as the Company's long-term investments in GICs with maturities of greater than one year increased to \$8,400,504 at June 30, 2024 from \$2,500,000 at December 31, 2024. Cash and short term investments of \$17,407,711 accounted for 69% of working capital as at June 30, 2024 as compared with cash and short-term investments of \$26,187,011 accounting for 86% of working capital as at December 31, 2023. The Company has sufficient cash and working capital to maintain its operating activities and to fund its planned growth and development activities.

The Company's business model does not require significant ongoing capital investment. This business model consistently generates cash from operations, providing the Company with significant cash

reserves not required in operations. The Company's cash reserves provide it with flexibility in the sourcing, financing, as well as commercialization of new product in-licensing and acquisition opportunities.

In addition to investment in growth (both in organic growth from existing brands and incremental growth from new brands), from time to time, excess capital may be returned to shareholders through Normal Course Issuer Bid share buybacks and cash dividends. Between December 10, 2018 and August 20, 2024, the Company repurchased and cancelled approximately 2.8 million common shares with a total expenditure of approximately \$18.7 million (at an average price per share of \$6.78).

On August 23, 2022, the Company's Board of Directors adopted a Dividend Policy. Subsequent quarterly cash dividends were declared and paid on the dates indicated in the table below:

Declaration Date	Record Date	Payment Date	Amount per Common Share
October 12, 2022	November 30, 2022	December 15, 2022	\$0.040
February 1, 2023	February 28, 2023	March 15, 2023	\$0.040
May 25, 2023	June 2, 2023	June 15, 2023	\$0.040
August 22, 2023	August 31, 2023	September 15, 2023	\$0.040
November 15, 2023	November 30, 2023	December 15, 2023	\$0.040
February 6, 2024	February 29, 2024	March 15, 2024	\$0.045
May 16, 2024	May 31, 2024	June 15, 2024	\$0.045
August 26, 2024	September 4, 2024	September 15, 2024	\$0.045


In addition to ongoing investments in growth and portfolio diversification, based on the Company's historical financial performance and planned future growth, the Board of Directors believes that share buybacks and cash dividends are also an effective use of capital in delivering long-term value to all BioSyent shareholders.

During H1 2024, there was a net decrease in cash, short-term and long-term investments of \$2,878,796 as compared to a net decrease of \$773,091 during H1 2023. With H1 2024 NIAT of \$3,349,016, the Company used \$554,753 of cash flows in operations after changes in non-cash working capital items during the period, including an increase in trade accounts receivable of \$2,179,321. Comparatively, with H1 2023 NIAT of \$2,658,436, the Company generated \$1,972,039 in cash flows from operations after changes in non-cash working capital during H1 2023.

The Company expended \$1,400,305 in H1 2024 for the repurchase and cancellation of its own common shares under a Normal Course Issuer Bid ("NCIB"). The Company also paid net aggregate cash dividends to common shareholders of \$1,045,363 during H1 2024, after increasing its quarterly dividend by 12.5% to \$0.045/share in Q1 2024. Comparatively, during H1 2023, the Company expended \$1,671,150 for the repurchase and cancellation of common shares under its NCIB and a further \$967,623 in cash dividends were paid to common shareholders (at \$0.04/share).

The graph below illustrates the company's cash, cash equivalents, short-term and long-term investments as of June 30, 2022, 2023, and 2024 as well as the growth over the comparative period:

Cash, Cash Equivalents and Investments at June 30



Total shareholders' equity increased to \$35,417,890 at June 30, 2024 from \$34,759,756 at December 31, 2023. While the Company generated comprehensive income of \$3,349,508 during H1 2024, it repurchased 162,300 of its own common shares during the period under its NCIB, reducing shareholders' equity by a total of \$1,400,305 as a result. Shareholders' equity was further reduced by the payment of net aggregate quarterly dividends of \$1,045,363 during the period. The Company's return on average equity for the TTM ending June 30, 2024 increased to 21% as compared to 16% for the TTM ending June 30, 2023.

The Company's total assets at June 30, 2024 were \$41,478,376 decreasing marginally compared to total assets of \$41,528,939 as at December 31, 2023. This compares to a decrease of 2% in total assets during H1 2023 to \$39,512,935 from total assets of \$40,485,264 at December 31, 2022.

The Company has no short term or long term debt; however, the Company has credit facilities available with Royal Bank of Canada totaling \$3,090,000, including a foreign exchange facility of \$1,500,000, a credit card facility of \$90,000, and a revolving demand credit facility of \$1,500,000 which had not been utilized as of June 30, 2024. This credit facility bears interest at a variable rate of Royal Bank prime plus 0.75% and has been secured with a General Security Agreement constituting a first ranking security interest of the Bank in the Company's property. The Company is subject to maintaining certain financial covenants if the demand credit facility is drawn upon.

Risk Management

The Company's risk management policies and financial results are presided over by the Company's Audit Committee, which reports to the Board of Directors of the Company (the "Board"). The pharmaceutical industry in which the Company operates is exposed to several risks due to a strict regulatory environment, an enhanced level of quality consciousness, competition from generic drug companies and heightened intellectual property litigation. The Company cannot predict or identify all risk factors nor can it accurately predict the impact, if any, of the risk factors on its business operations or the extent to which a factor, event or any such combination may materially change future results of the Company's financial position from those reported or projected in

any forward-looking statements. Accordingly, the Company cautions the reader not to rely on reported financial information and forward-looking statements to predict actual future results.

This report and the accompanying financial information should be read in conjunction with this statement concerning risks and uncertainties. Some of the risks, uncertainties and events that may affect the Company, its business, operations and results are given in this section. However, the factors and uncertainties are not limited to those stated.

The Company has policies and practices mandated by the Board to manage the Company's risks. Such risks include the following:

1. Sourcing and Revenue Concentration

Some raw materials used in production are sourced from a single supplier and the Company is exposed to the same business risks that the supplier may experience. In line with other pharmaceutical companies, the Company sells its products primarily through a limited number of wholesalers and retail pharmacy chains.

2. Foreign Exchange Risk

The Company currently earns revenue in Canadian dollars ("CAD"), U.S. dollars ("USD"), and Euros ("EUR") and incurs costs in Canadian dollars, U.S. dollars, and Euros. Management monitors the U.S. dollar and Euro net liability position on an ongoing basis during the period and adjusts the total net monetary

liability balance accordingly. When it is appropriate to de-risk future foreign exchange transactions, the Company uses Dual Currency Deposits, foreign exchange options, and forward purchase contracts to manage foreign exchange transaction exposure.

3. Interest Rate Risk

Interest rate risk is the risk that the future cash flow of a financial instrument will fluctuate because of changes in interest rates. Some of the Company's cash and cash equivalents as at the date of the Company's Consolidated Statements of Financial Position are invested in redeemable guaranteed investment certificates (each, a "GIC"), which earn interest at fixed rates during their tenure. The Company's short-term and long-term investments consist of non-redeemable GICs which also earn interest at fixed rates during their tenure.

The Company manages its interest rate risk by maximizing the interest income earned on excess funds while maintaining the liquidity necessary to conduct operations on a day-to-day basis. Fluctuations in market rates of interest when these GICs are renewed may have an impact on the Company's Finance Income for the period. Changes to the Bank of Canada's Policy Interest Rate will affect market rates of interest and the rate of interest earned on the Company's GICs.

4. Credit Risk

Credit risk is the risk of financial loss to the Company if a customer or counterparty to a financial instrument fails to meet its contractual obligations and arises principally from the Company's cash and cash equivalents, short term investments, trade and other receivables, and loans receivable. The carrying amount of financial assets represents maximum credit exposure. As the Company invests in GICs with Canadian Chartered Banks, its credit risk on this account is negligible. The Company's loans receivable (see Note 11 of the Consolidated Financial Statements) are full recourse and secured by a pledge of common shares of the Company purchased by the Borrowers, who are key management personnel. Based on these factors, the Company considers the credit risk associated with these

loans receivable to be low. There are no factors at the end of the period to indicate a significant increase in credit risk has occurred and there are no defaults on the loans receivable.

a. Aging of Receivables

The majority of the Company's current customers are corporations with whom the Company has transacted for several years. In assessing the credit risk of its trade accounts receivable, the Company considers historical default rates and payment patterns, the nature of its customer base, and forward-looking information including any anticipated changes to its customer base, credit terms, and pricing.

The Company's gross trade accounts receivable at June 30, 2024 of \$5,051,188 increased by 46% as compared to gross trade accounts receivable of \$3,459,109 at June 30, 2023 as a function of the 15% overall increase in sales in H1 2024 versus H1 2023 as well as the timing of several large sales to pharmaceutical wholesaler customers late in the period which were collected subsequent to June 30, 2024. To the date hereof, the Company has subsequently collected 81% of accounts receivable outstanding at June 30, 2024.

The Company has provided for expected credit losses of \$73,985 (December 31, 2023 - \$92,452) related primarily to disputed deductions on trade receivables adjusted for forward looking factors specific to certain Canadian pharmaceutical wholesale customers.

b. Concentration of Receivables

As of June 30, 2024, one customer represents 39% of net trade receivables (December 31, 2023 - 42%) while another customer represents 30% of net trade receivables (December 31, 2023 - 16%), a third customer represents 12% of net trade receivables (December 31, 2023 - 19%), and a fourth customer represents 6% of net trade receivables (December 31, 2023 - 10%).

c. Loans Receivable

The Company advanced loan proceeds totalling \$391,500 on May 26, 2017, and a further \$175,000 on December 11, 2018, in accordance with the terms of the MSLP for the purchase of the Company's common shares by the Borrowers.

Each full recourse MSLP participant's loan (collectively, the "MSLP Participant Loans") bore interest at rates ranging from 1.00% - 3.00% per annum and had a maturity date of five years for the date that the loan was advanced, being either May 26, 2022 or December 11, 2023 (the "original Maturity Dates").

On March 9, 2022, the Board approved an amendment of the MSLP loans which provided for an extended repayment schedule. On May 26, 2022, the Company entered into amended loan agreements with certain Borrowers under this extended repayment schedule. Under the terms of these amended loan agreements, the Borrowers were required to repay 10% of the MSLP loan principal amount plus any and all accrued interest on the MSLP loan principal amount as of May 26, 2022. The MSLP loan principal amounts which remain outstanding following such repayment continue to bear interest at a prescribed rate of 6.00% per annum for the six months ended June 30, 2024, with annual repayments of 20% of such remaining MSLP loan principal amounts plus accrued interest thereon due and payable by the Borrowers on each of May 26, 2023, May 26, 2024, May 26, 2025, and May 26, 2026 with the final repayment for all MSLP loans due and payable no later than May 26, 2027 (the "extended Maturity Date").

The modification of certain MSLP loans on May 26, 2022 resulted in no change to the gross carrying amount of such loans; as such, the Company recognized no modification gain or loss on these MSLP loans.

On December 11, 2023, the Company entered into an amended loan agreement with a certain Borrower under this extended repayment schedule. Under the terms of this amended loan agreement, the Borrower was required to repay 10% of the MSLP loan principal amount plus any and all accrued interest on the

MSLP loan principal amount as of and on December 11, 2023. The MSLP loan principal amount which remains outstanding following such repayment continues to bear interest at a prescribed rate of 6.00% per annum for the six months ended June 30, 2024 with annual repayments of 20% of such remaining MSLP loan principal amounts plus accrued interest thereon due and payable by the Borrower on each of December 11, 2024, December 11, 2025, and December 11, 2026 with the final 40% repayment due and payable no later than May 26, 2027.

The modification of this MSLP loan on December 11, 2023 resulted in no change to the gross carrying amount of such loan; as such, the Company recognized no modification gain or loss on this MSLP loan.

All common shares of the Company purchased with the proceeds of a loan are required to be pledged as security for the satisfaction and performance of the loan obligations. If the Borrower ceases to be employed by the Company or a subsidiary of the Company prior to the end of the original Maturity Dates or the extended Maturity Date, as applicable, all outstanding loan obligations shall become due and payable on the thirtieth (30th) day following the date of termination. In addition, in the event of a default by the Borrower of the terms of the loan, the loan obligations will become due and payable immediately.

Subject to the pledge on the common shares in favour of the Company, the Borrower is the sole owner of all common shares purchased on its behalf pursuant to the MSLP. All proceeds from the sale of common shares acquired through the MSLP are expected to be directed to the Company until the loan obligations have been satisfied in full.

Interest receivable of \$7,717 was accrued on the loans for the six months ended June 30, 2024 (six months ended June 30, 2023 - \$9,930) at a prescribed interest rate of 6.00% per annum (six months ended June 30, 2023 - 4.00% - 5.00% per annum) and has been included in finance income on the Company's Consolidated Statements of Comprehensive Income.

As the loans are full recourse loans, they have not been accounted for as stock-based compensation, but as financial instruments within the scope of IFRS 9, Financial Instruments.

d. Cash and Cash Equivalents and Short-term Investments

Cash, cash equivalents, short-term and long-term investments are maintained with Canadian financial institutions and the wholly owned subsidiaries of these financial institutions. Deposits held with banks may exceed the amount of insurance provided on such deposits. Generally, these deposits may be redeemed upon demand and are maintained with financial institutions of reputable credit and therefore bear minimal credit risk.

5. Liquidity Risk

Liquidity risk is the risk that the Company will not be able to meet its obligations as they fall due. The Company manages its liquidity risk by forecasting cash flows from operations and anticipated investing and financing activities. Senior management is actively involved in the review and approval of planned expenditures. All contractual maturities of accounts payable and accrued liabilities are due within one year. The Company has no other liabilities.

The Company generates sufficient cash from operating activities to fund its operations and fulfill its obligations as they become due. The Company has credit facilities available with Royal Bank of Canada totalling \$3,090,000, including a revolving demand credit facility of \$1,500,000 which it has not drawn down as at the date hereof, a foreign exchange facility of \$1,500,000, and credit card facilities totalling \$90,000. The Company's funds have not been committed in any way, except as set out in Note 20 of the Consolidated Financial Statements.

6. Information Technology (IT)

The integrity, reliability, and security of information in all forms are critical to the Company's operations and inaccurate, incomplete or unavailable information could lead to incorrect financial reporting, poor decisions, privacy breaches, and/ or inappropriate disclosure of sensitive information.

The Company is reliant on the integrity of its IT systems, hardware, software and certain other IT infrastructure in maintaining business continuity and in securing proprietary and sensitive information as well as certain of its financial assets. The Company has implemented comprehensive IT security policies and controls in order to safeguard its assets and sensitive information and to maintain business continuity in the event of potential disruptions.

The integrity of the Company's IT systems is exposed to a risk of malicious and unauthorized breaches by outside parties acting unlawfully. While extensive, the Company's IT security policies and controls cannot guarantee that such unauthorized breaches, whether targeted or opportunistic in nature, will not occur in the future. Such a breach could result in loss of financial assets through fraud, loss of sensitive information, reputational loss, or disruption of operations and business continuity.

The Company monitors its exposure to IT security risks on a continual basis and modifies its IT security policies, practices, infrastructure and insurance coverage as needed to address the assessed level of such risk.

7. Competition

The pharmaceutical industry is characterized by intense competition and the Company is faced with the risk of enhanced competitive activity which may impact operational results.

8. Climatic Conditions

The Legacy Business is dependent on agricultural production which, in turn, is impacted by climatic variations which may affect demand for its products.

9. General Economic Conditions

The Company has no control over changes in inflation, input prices, the availability of raw materials and labour, interest rates, foreign currency exchange rates and controls or other economic factors affecting its businesses, including uncertainty surrounding the economic impact of disease epidemics and pandemics and the

risk of supply chain interruptions related thereto, geopolitical risks, armed conflicts, economic sanctions or the possibility of political unrest, legal or regulatory changes in jurisdictions in which the Company or its customers operate. These factors could negatively affect the Company's future results of operations.

10. Innovation

The competitiveness of the Company's products is subject to continuous innovation within the pharmaceutical industry. The Company tries to maintain the relevance of its products to the market but is exposed to new improved innovations that can undermine the competitiveness of its products.

11. Width of Product Portfolio

While the Company continuously strives to increase the portfolio of products in its commercialization pipeline, the high cost of acquiring new products and the long lead-time for bringing these products to market creates a dependency on a limited range of products at this time.

12. Capital Risk

Significant capital investment is required in the sourcing, development, and launch of new products to the market as a result of the high cost of product development as well as the high level of competition and regulation in the pharmaceutical industry. Competitive, regulatory, and market risks result in a high degree of new product failures in the specialty pharmaceutical industry. Given the substantial resources and investment required in launching new products, there is uncertainty that the returns on such investment will meet Company expectations as well as a risk of financial loss for unsuccessful product launches.

13. Agreements Relating to the Development and Distribution of Products Internationally

The Company currently has several collaboration or distribution agreements relating to the marketing and distribution of FeraMAX[®] products in international markets. The Company relies on these agreements because it does not wish to market its products directly in these markets. The Company intends to secure additional agreements relating to the marketing and distribution of FeraMAX[®] and any other product for which it may receive commercial rights outside of Canada.

The Company may be unable to enter into in-licensing agreements for the development of new products and out-licensing agreements for the distribution of its existing products. The Company also faces and will continue to face, significant competition in seeking appropriate collaborators and marketing and distribution partners. Moreover, collaboration and distribution arrangements are complex and time-consuming to negotiate, document and implement.

Reliance on these agreements exposes the Company to a number of risks, including the following:

- Collaborators and marketing and distribution partners may not devote sufficient resources to the Company's products or product candidates;
- Disputes may arise with respect to payments that the Company believes are due under such distribution and collaboration agreements;
- Unwillingness on the part of collaborators and marketing and distribution partners to provide updates regarding the progress of its development, commercialization or marketing activities, or to permit public disclosure of these activities;
- Collaborators and marketing and distribution partners may terminate the relationship; disputes may arise in the future with respect to the ownership of rights to technology developed with collaborators;
- Disagreements with collaborators and marketing and distribution partners could result in litigation or arbitration;

- Collaborators may elect to pursue the development of any additional product candidates and pursue technologies or products either on their own or in collaboration with other parties, including competitors;
- Collaborators and marketing and distribution partners may pursue higher priority programs or change the focus of their programs, which could affect the collaborators' and marketing and distribution partners' commitment to their respective territories;
- Collaborators and marketing and distribution partners may develop or distribute products that compete with the Company's products; and
- The Company's pharmaceutical products are distributed to international markets where political and economic risks and uncertainties may exist. These risks and uncertainties could adversely affect the distribution of the Company's products to such markets.

The occurrence of any of these or other events may impair commercialization of the Company's products.

14. Regulatory Risks

With respect to BioSyent's Legacy Business, regulatory and legislative requirements affect the development, manufacture and distribution of BioSyent's products, including the testing and planting of seeds containing its biotechnology traits and the import of crops grown from those seeds. Non-compliance can harm sales and profitability. The failure to receive necessary permits or approvals could have near and long-term effects on BioSyent's ability to produce and sell some current and future products.

With respect to BioSyent's Pharmaceutical Business, the sale of pharmaceutical products is highly regulated, which significantly increases the difficulty and costs involved in obtaining and maintaining regulatory approval for marketing new and existing products.

Various business interruption risks inherent to the pharmaceutical industry, like product recalls, adverse drug reactions, quality issues and issues relating to good manufacturing practices may impact the financial results if they transgress regulatory boundaries.

The regulatory approval process can be long and may involve significant delays despite the Company's best efforts. There is also a risk that the Company's products may be withdrawn from the market and the required approvals suspended as a result of non-compliance with regulatory requirements. The extent of such regulation is increased for products designated by Health Canada as Controlled Substances, such as the Tibella[®] women's health product. As a result, the Company's costs of regulatory compliance and risks associated with non-compliance are higher for such Controlled Substances than for other non-controlled pharmaceutical products which it markets and sells.

Furthermore, there can be no assurance that the regulators will not require modification to any submissions, which may result in delays or failure to obtain regulatory approvals. Any delay or failure to obtain regulatory approvals could adversely affect the ability of the Company to utilize its technology, thereby adversely affecting operations. Further, there can be no assurance that the Company's products will prove to be safe and effective in clinical trials or receive the requisite regulatory approval.

15. Specific Risks

The Company has insurance policies in place against risks relating to general commercial liability, product liability, product recall, loss of Company assets, IT security, and business interruption. The Company reviews its insurance coverage on a regular basis as part of its risk management program and adjusts this coverage as appropriate, based its current risk profile and operations. The Company is exposed to the potential risk that claims made on the Company or losses incurred may be in excess of the level of insurance coverage undertaken by the Company.

Disclosure of Outstanding Share Data

The authorized share capital of the Company consists of 100,000,000 common shares without par value and 25,000,000 preferred shares without par value. The holders of the preferred shares as a class shall not be entitled to receive notice of, to attend or to vote at any meeting of the shareholders of the Company.

As at August 26, 2024 the following common shares, stock options, and Restricted Share Units were outstanding:

	No. of Shares	Exercise Price Range
Issued common shares	11,791,299	
Treasury shares: RSU Plan in Trust	(204,385)	
Outstanding common shares	11,586,914	
Stock options outstanding	147,491	\$6.20 - \$ 10.97
RSUs outstanding	202,139	
Fully Diluted at August 26, 2024	11,936,544	

Normal Course Issuer Bid

On December 13, 2023, the Company announced that the TSX Venture Exchange had accepted its Notice of Intention to Make a NCIB for a further 12-month period ending on December 18, 2024 during which the Company would be permitted to purchase up to 650,000 of its own common shares for cancellation. 171,600 common shares have been repurchased and cancelled by the Company under this NCIB between December 19, 2023 and the date hereof.

Restricted Share Unit Plan

On March 4, 2020, the Board of Directors adopted a Restricted Share Unit ("RSU") Plan which was approved by shareholders on May 27, 2020 and which was subsequently approved by the TSX

Venture Exchange. The RSU Plan was established as a vehicle by which equity-based incentives may be granted to eligible employees, consultants, directors and officers of the Company to recognize and reward their contributions to the long-term success of the Company including aligning their interests more closely with the interests of the Company's shareholders. The RSU Plan is a fixed plan which reserves for issuance a maximum of 800,000 common shares of the Company.

As of the date hereof, 204,385 of the Company's own common shares were held in trust pursuant to its RSU Plan for future settlement of vested RSUs granted to employees, senior management, and directors of the Company. As of the date hereof, there are 202,139 unvested RSUs outstanding.

Commitments

Office Leases

The Company's office lease agreement commenced on September 1, 2019 and extends to August 31, 2029.

The Company's undiscounted minimum future rental payments and estimated occupancy costs (including certain operating costs and realty taxes) for the next five fiscal years under this lease agreement as of the date hereof are approximately as follows:

Fiscal Year	Rent and Occupancy Costs
2024	\$ 148,635
2025	\$ 381,605
2026	\$ 388,633
2027	\$ 388,633
2028	\$ 388,633
Beyond Next 5 Fiscal Years	\$ 259,089
Total	\$ 1,955,228

Purchase Commitments

In the normal course of business, the Company has minimum purchase commitments with certain of its suppliers.

Disclosure Controls

The Company constantly endeavours to allow for greater segregation of duties and operating level controls within the constraints of its operating infrastructure. While intending to strengthen both these aspects of internal control, the Company believes that strong management supervisory controls minimize the possibility of erroneous financial reporting.

The certifying officers of the Company have opted not to certify the design and evaluation of the Company's disclosure controls and procedures ("DC&P") and internal control over financial reporting ("ICFR"). Inherent limitations on the ability of the certifying officers to design and implement (on a cost-effective basis) DC&P and ICFR for the Company may result in additional risks to the quality, reliability, transparency and timeliness of interim and annual filings and other reports provided under securities legislation.

Investor Relations Activities

Investor relations functions were accomplished through personnel whose duties include dissemination of news releases, investor communications and general day-to-day operations of the Company. Mr. René Goehrum, President and CEO, Mr. Robert March, Vice President and CFO, and Mr. Joost van der Mark, Vice President, Corporate Development, assist in the implementation of the Company's investor relations program.

Related Party Transactions

Key Management Personnel Compensation

Key management personnel are those persons having authority and responsibility for planning, directing and controlling the activities of the Company and/or its subsidiaries, directly or indirectly.

The table below summarizes compensation for key management personnel of the Company for the three and six months ended June 30, 2024 and 2023:

	Three months ended June 30,		Six months ended June 30,	
	2024	2023	2024	2023
Number of Key Management Personnel	7	6	7	6
Salary, Benefits, and Bonus	\$ 433,748	\$340,218	\$ 777,039	\$671,768
Share-Based Payments	\$ 107,223	\$103,770	\$ 198,383	\$177,261

During the six months ended June 30, 2024, the Company recorded share-based payment expense of \$198,383 (six months ended June 30, 2023 - \$177,261) related to the amortization of RSUs granted to key management under the Company's RSU Plan, the vesting of options granted prior to 2020 under the Company's SOP, as well as the Company's contributions to the ESPP for the purchase of common shares on behalf of participating key management personnel.

As at June 30, 2024, there were loans receivable under the MSLP from key management personnel of \$223,624 (December 31, 2023 - \$274,601). During the six months ended June 30, 2024, MSLP loan repayments of \$58,694 were received (six months ended June 30, 2023 - \$68,765). Interest accrued on these MSLP loans during the six months ended June 30, 2024 totalled \$7,717 (six months ended June 30, 2023 - \$9,450).

Transactions with Directors

During the six months ended June 30, 2024, the Company paid cash fees to its directors in the amount of \$63,564 (six months ended June 30, 2023 - \$64,594) and recorded share-based payments

expense for accounting purposes of \$41,229 (six months ended June 30, 2023 - \$40,586) related to the amortization of RSUs under the Company's RSU Plan.

Legal Proceedings

From time to time the Company may be exposed to claims and legal actions in the normal course of business. As of the date hereof, the Company was not aware of any litigation or threatened claims either outstanding or pending.